STOCK TITAN

Intercept Pharmaceuticals to Participate in H.C. Wainwright’s 6th Annual NASH Investor Conference on October 17, 2022

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Intercept Pharmaceuticals (Nasdaq: ICPT) announced that Jerry Durso, CEO, and Dr. Michelle Berrey, President of R&D, will participate in a fireside chat at H.C. Wainwright's 6th Annual NASH Investor Conference on October 17, 2022. The chat is scheduled from 2:30 p.m. to 3:00 p.m. ET. Investors interested in attending can register for the conference. The company focuses on developing novel therapies for progressive non-viral liver diseases, including primary biliary cholangitis and nonalcoholic steatohepatitis.

Positive
  • None.
Negative
  • None.

MORRISTOWN, N.J., Oct. 12, 2022 (GLOBE NEWSWIRE) -- Intercept Pharmaceuticals, Inc. (Nasdaq: ICPT), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, today announced that Jerry Durso, President and Chief Executive Officer, and Dr. Michelle Berrey, President of R&D and Chief Medical Officer of Intercept will participate in a fireside chat at H.C. Wainwright’s 6th Annual NASH Investor Conference, taking place virtually on Monday, October 17, 2022. The Company will also conduct meetings with investors.

Intercept’s fireside chat will take place from 2:30 p.m. - 3:00 p.m. ET. To view the fireside chat please register for the H.C Wainwright NASH Investor Conference here. Investors attending the conference who wish to meet with the Intercept management team, please reach out to your H.C. Wainwright representative or contact Nareg Sagherian.

About Intercept
Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat progressive non-viral liver diseases, including primary biliary cholangitis (PBC) and nonalcoholic steatohepatitis (NASH). For more information, please visit www.interceptpharma.com or connect with the company on Twitter and LinkedIn.

Contact
For more information about Intercept, please contact:

Investor inquiries: investors@interceptpharma.com
Media inquiries: media@interceptpharma.com


FAQ

When will Intercept Pharmaceuticals participate in the NASH Investor Conference?

Intercept Pharmaceuticals will participate in the NASH Investor Conference on October 17, 2022.

Who from Intercept Pharmaceuticals will speak at the NASH Investor Conference?

Jerry Durso, CEO, and Dr. Michelle Berrey, President of R&D, will speak at the NASH Investor Conference.

What is the time of Intercept's fireside chat at the NASH Investor Conference?

The fireside chat will take place from 2:30 p.m. to 3:00 p.m. ET.

How can investors view the fireside chat of Intercept Pharmaceuticals?

Investors can view the fireside chat by registering for the H.C. Wainwright NASH Investor Conference.

What are the main diseases Intercept Pharmaceuticals focuses on?

Intercept Pharmaceuticals focuses on progressive non-viral liver diseases, including primary biliary cholangitis and nonalcoholic steatohepatitis.

Intercept Pharmaceuticals, Inc.

NASDAQ:ICPT

ICPT Rankings

ICPT Latest News

ICPT Stock Data

794.69M
40.45M
3.13%
81.3%
24.24%
Biotechnology
Healthcare
Link
United States
Morristown